International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 13, Issue-12
December, 2023, P05
ISSN: 2319-9253

EDGE ARTIFICIAL INTELLIGENCE IN ONCOLOGY: REAL-TIME CANCER DIAGNOSTICS AND INTELLIGENT CLINICAL MONITORING

[#1]**Dr. Pavan Shetty,** Professor, Department of Surgical Oncology,
KVG Medical College and Hospital, Sullia, India
Pavanshetty83@gmail.com

Abstract: Edge artificial intelligence (Edge AI) is emerging as a transformative technology in precision oncology by enabling real-time processing of biomedical data directly at or near the point of care, thereby reducing latency, enhancing data privacy, and supporting intelligent clinical monitoring throughout the cancer care continuum. Unlike conventional cloud-dependent artificial intelligence systems, Edge AI integrates computational intelligence within medical imaging devices, digital pathology platforms, wearable biosensors, mobile health technologies, and Internet of Medical Things (IoMT) infrastructure to provide immediate clinical insights without requiring continuous remote computation. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled comprehensive integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes into intelligent edge computing ecosystems. These systems support early cancer detection, biomarker discovery, molecular characterization, prognostic prediction, therapeutic optimization, immunotherapy selection, adaptive disease monitoring, digital twin simulation, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, explainable artificial intelligence, agentic AI, cloud-edge hybrid architectures, and 6G-enabled healthcare networks further strengthen Edge AI by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite remarkable technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding computational resource constraints, multimodal data harmonization, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of Edge AI in oncology, emphasizing real-time cancer diagnostics and intelligent clinical monitoring as transformative technologies for next-generation precision cancer care.[1]

Keywords: *Edge artificial intelligence, Precision oncology, Foundation models, Computational oncology, Digital pathology, Real-time diagnostics, Intelligent monitoring, Wearable technologies, Clinical decision support, Personalized medicine.*

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and intricate interactions among malignant cells, stromal components, immune populations, vascular structures, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon intelligent computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern oncology generates enormous quantities of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory

Paper Available at: ***www.ijarai.com***
DOI : https://doi.org/10.65713/ijaraiv13i1205

investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, biomedical literature, and patient-reported outcomes. Although each modality contributes valuable biological insight, centralized cloud processing frequently introduces latency, communication dependency, privacy concerns, and computational bottlenecks that may delay critical clinical decisions.[3]

Edge artificial intelligence addresses these challenges by performing intelligent computation directly within medical devices, imaging systems, wearable sensors, mobile platforms, and healthcare infrastructure while enabling rapid clinical decision-making close to the point of care. Combined with foundation AI models and multimodal learning, Edge AI establishes a transformative framework for real-time precision oncology.

2. Evolution of Edge Artificial Intelligence in Oncology

Artificial intelligence in oncology has evolved from centralized statistical analyses toward distributed intelligent healthcare ecosystems capable of performing real-time biomedical computation. Early computational systems primarily relied upon cloud-based machine learning algorithms developed for isolated diagnostic or prognostic tasks. Although these systems demonstrated important clinical value, they remained constrained by communication latency, dependence upon high-bandwidth infrastructure, fragmented biomedical information, and limited real-time responsiveness.[4]

Deep learning substantially expanded computational capabilities through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Advances in specialized AI hardware, embedded processors, edge accelerators, and efficient transformer architectures subsequently enabled deployment of sophisticated computational models directly on clinical devices.

Foundation AI models, federated learning, digital twins, multimodal large language models, and cloud-edge collaborative architectures now establish intelligent distributed ecosystems capable of supporting adaptive precision oncology at the point of care.[5]

3. Principles of Edge Artificial Intelligence

Edge artificial intelligence differs fundamentally from conventional cloud-based artificial intelligence because computational reasoning occurs directly within medical devices, wearable sensors, imaging systems, or local healthcare infrastructure rather than exclusively within centralized cloud platforms. Foundation AI models integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories into unified patient-specific computational representations while performing local inference.[6]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align heterogeneous biomedical modalities within unified computational embedding spaces. Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes.

These computational principles establish intelligent edge computing capable of supporting adaptive precision oncology through secure, low-latency biomedical intelligence.[7]

4. Computational Architecture

Modern Edge AI oncology platforms consist of interconnected computational layers responsible for biomedical data acquisition, local preprocessing, multimodal representation learning, adaptive inference, cloud-edge synchronization, predictive analytics, digital twin simulation, and intelligent clinical decision support.[8]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, laboratory investigations, circulating tumor DNA, wearable

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1205

physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Local preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, synchronize temporal patient information, and optimize computational efficiency for edge deployment.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories while enabling rapid local inference and periodic synchronization with cloud-based computational resources.[9]

5. Edge AI for Real-Time Cancer Diagnostics

One of the most important applications of Edge AI is real-time cancer diagnosis through immediate analysis of radiological imaging, digital pathology, laboratory biomarkers, and molecular diagnostics directly within clinical environments. Foundation AI models deployed on edge devices automatically identify suspicious imaging abnormalities, histopathological patterns, molecular biomarkers, and diagnostic features while minimizing latency associated with cloud communication.[10]

Radiological imaging systems equipped with embedded AI processors can provide immediate lesion detection during image acquisition, while digital pathology scanners perform rapid tissue classification during slide digitization. Portable diagnostic devices further enable decentralized cancer screening in resource-limited environments through locally executed artificial intelligence.

These capabilities substantially improve diagnostic efficiency, accelerate clinical workflows, reduce delays, and enhance accessibility of precision oncology.[11]

6. Intelligent Clinical Monitoring

Continuous patient monitoring represents one of the greatest strengths of Edge AI in oncology. Wearable biosensors, smart medical devices, implantable sensors, and mobile health technologies continuously measure physiological parameters including heart rate, respiratory rate, temperature, oxygen saturation, sleep quality, physical activity, medication adherence, treatment-related symptoms, and quality-of-life indicators.[12]

Foundation AI models integrate these physiological measurements with laboratory biomarkers, radiological imaging, digital pathology, molecular biology, and longitudinal clinical information using multimodal transformers and graph neural networks. Local edge processing enables immediate identification of clinically significant physiological changes while reducing communication latency and protecting patient privacy.

These intelligent monitoring systems substantially improve prediction of treatment toxicity, disease progression, hospitalization risk, survivorship outcomes, and early clinical intervention.[13]

7. Multimodal Biomedical Intelligence

Comprehensive Edge AI oncology depends upon seamless integration of complementary biomedical modalities into unified patient-specific computational representations. Radiological imaging provides anatomical and functional characterization of tumors, digital pathology reveals microscopic tissue architecture, and multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, and spatial biology—provide comprehensive molecular characterization of evolving cancer biology.[14]

Artificial intelligence harmonizes these diverse biomedical modalities using multimodal transformers, graph neural networks, biological knowledge graphs, and cross-modal attention mechanisms capable of generating adaptive computational embeddings representing continuously evolving patient biology while performing efficient edge-based inference.

These multimodal representations substantially improve diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, and adaptive disease monitoring throughout precision oncology.[15]

8. Privacy-Preserving Edge Intelligence

Protection of patient privacy represents one of the major advantages of Edge AI. Because computation occurs locally on medical devices or institutional infrastructure, sensitive biomedical information frequently remains within healthcare environments rather than being continuously transmitted to external cloud platforms.[16]

Federated learning further strengthens privacy by enabling collaborative model development through decentralized parameter exchange rather than direct sharing of patient data. Combined with encryption, secure hardware, trusted execution environments, and differential privacy, Edge AI substantially reduces cybersecurity risks while maintaining high-quality computational performance.

These privacy-preserving architectures establish trustworthy computational ecosystems supporting responsible implementation of precision oncology.[17]

9. Personalized Therapeutic Monitoring

One of the most clinically significant applications of Edge AI is personalized therapeutic monitoring through continuous integration of molecular biology, imaging phenotypes, laboratory biomarkers, wearable physiological monitoring, medication history, physician documentation, and longitudinal clinical trajectories. Foundation AI models deployed at the edge continuously evaluate treatment responsiveness, toxicity profiles, physiological adaptation, medication adherence, symptom progression, and recurrence risk while generating individualized therapeutic recommendations in real time. These adaptive computational systems establish a comprehensive framework for continuous personalized cancer monitoring capable of improving patient outcomes throughout the cancer care continuum.[18][19][20]

10. Digital Twins and Edge-Based Virtual Patient Modeling

Digital twin technology represents one of the most transformative applications of Edge Artificial Intelligence in oncology by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts through local and cloud-edge computational infrastructures. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]

Unlike conventional cloud-dependent predictive models, edge-enabled digital twins continuously update their computational representations using locally acquired biomedical information before selectively synchronizing with centralized healthcare systems. Integration of multimodal molecular biology with predictive simulation enables virtual patients to evaluate alternative therapeutic strategies, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology while minimizing communication latency.

By combining multimodal biomedical intelligence with distributed predictive simulation, edge-enabled digital twins transform computational oncology from retrospective analysis toward proactive, continuously adaptive, and real-time precision medicine.

11. Intelligent Clinical Decision Support

Edge Artificial Intelligence provides the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations directly at the point of care. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, foundation AI models deployed on edge platforms synthesize these diverse biomedical information sources into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, biomarker analyses, molecular interpretations, digital twin simulations, therapeutic recommendations,

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1205

toxicity estimates, recurrence probabilities, disease progression forecasts, survival predictions, and real-time treatment response assessments while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, biomedical engineers, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce information fragmentation, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Edge Intelligence

A defining characteristic of Edge AI oncology platforms is the ability to continuously evolve as new biomedical information becomes available while performing local computational inference. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, biomedical literature, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes diagnostic and therapeutic recommendations through iterative evaluation of treatment outcomes. Hybrid cloud-edge architectures further enable synchronization of locally learned knowledge with global computational models while preserving privacy and minimizing communication overhead.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time precision medicine even in decentralized clinical environments.

13. Federated Edge AI Networks

Development of highly generalizable Edge AI oncology platforms requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, wearable ecosystems, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local edge models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, transparency, and generalizability across diverse healthcare environments.

Federated edge oncology ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible biomedical data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of Edge Artificial Intelligence in oncology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, multimodal attention mapping, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, secure edge hardware, trusted execution environments, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, continuous post-deployment surveillance, and multidisciplinary oversight to ensure trustworthy integration of Edge AI into routine oncology practice.

15. Future Perspectives

Future Edge AI oncology ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, 6G communication technologies, and autonomous clinical reasoning systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence through intelligent cloud-edge collaboration.

Such distributed intelligent ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Edge Artificial Intelligence represents one of the most significant paradigm shifts in computational oncology by integrating real-time biomedical computation, radiological imaging, digital pathology, molecular biology, laboratory biomarkers, wearable technologies, digital twins, and longitudinal clinical intelligence into distributed computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional cloud-dependent artificial intelligence systems, Edge AI enables immediate clinical reasoning at the point of care while reducing latency, enhancing privacy, improving resilience, and supporting decentralized healthcare delivery.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, remote patient monitoring, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of Edge AI to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, secures edge hardware, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, Edge Artificial Intelligence is expected to become a foundational computational infrastructure supporting intelligent precision oncology worldwide.

17. Conclusion

Edge Artificial Intelligence is transforming precision oncology by integrating real-time diagnostics, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into distributed computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and

Paper Available at: *www.ijarai.com*
DOI : https://doi.org/10.65713/ijaraiv13i1205

individualized clinical decision-making throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, cloud-edge computing, and generative artificial intelligence are expected to further strengthen intelligent oncology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical decision-making, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of Edge Artificial Intelligence in oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, distributed, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
3. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
4. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321, DOI: https://doi.org/10.46121/pspc.51.4.4
5. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304, DOI: https://doi.org/10.46121/pspc.51.2.7
6. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
7. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323, DOI: https://doi.org/10.46121/pspc.51.4.5
8. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388, DOI: https://doi.org/10.46121/pspc.51.4.7
9. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
10. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
11. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
12. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical

Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
13. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
14. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
15. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
16. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
17. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
18. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
19. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
20. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
21. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
22. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
23. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
24. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
25. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
26. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
27. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
28. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
29. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
30. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.